clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Erythema Nodosum D004893 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Splenic Diseases D013158 5 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Whooping Cough D014917 6 associated lipids
Bronchitis D001991 6 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Metaplasia D008679 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Bacteriuria D001437 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Fistula D005402 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Leprosy D007918 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urination Disorders D014555 9 associated lipids
Urethritis D014526 9 associated lipids
Sinusitis D012852 9 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Pancreatitis D010195 10 associated lipids
Dyspnea D004417 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Influenza, Human D007251 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Otitis Media D010033 12 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Radiation Injuries D011832 14 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Dermatomycoses D003881 17 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Peptic Ulcer D010437 19 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Yoon H et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? 2013 J. Gastroenterol. Hepatol. pmid:24118110
Calza P et al. Fate of selected pharmaceuticals in river waters. 2013 Environ Sci Pollut Res Int pmid:22851223
Laving A et al. Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya. 2013 S. Afr. Med. J. pmid:24300630
Cecchini MP et al. Might Helicobacter pylori infection be associated with distortion on taste perception? 2013 Med. Hypotheses pmid:23845559
Delgado JS et al. Granulomatous gastritis and Helicobacter pylori infection. 2013 Isr. Med. Assoc. J. pmid:23882902
Ang TL et al. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. 2013 J Dig Dis pmid:23253473
Kazama I and Maruyama Y Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. 2013 Pharm Biol pmid:23527897
Sardarian H et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. 2013 Helicobacter pmid:23121338
Goh IX et al. Cytochrome P450 drug interactions with statin therapy. 2013 Singapore Med J pmid:23546024
Maggi P et al. Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsycotic drugs. 2013 Immunopharmacol Immunotoxicol pmid:22804484
Hong SK et al. First case of Mycobacterium longobardum infection. 2013 Ann Lab Med pmid:24003427
Faraji F et al. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. 2012 Nov-Dec Pain Physician pmid:23159967
Eremenko AA et al. [Effect of clarithromycin on the systemic inflammatory response syndrome severity in patients after myocardial revascularization surgery]. 2012 May-Jun Anesteziol Reanimatol pmid:22993930
Singh V et al. Vesicular palmoplantar pityriasis rosea. 2012 Mar-Apr Skinmed pmid:22545332
Gutiérrez-Castrellón P et al. Efficacy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysis. 2012 Mar-Apr Rev. Invest. Clin. pmid:22991774
Rajendiran S et al. Increased protein carbonylation and decreased antioxidant status in anemic H. pylori infected patients: effect of treatment. 2012 Jul-Aug Saudi J Gastroenterol pmid:22824768
De Sanctis V et al. Anti-Helicobacter pylori therapy in primary MALT lymphoma of rectum. 2012 Jul-Aug Tumori pmid:23052174
Figueroa M et al. [Antimicrobial susceptibility of Helicobacter pylori with chronic gastritis]. 2012 Jan-Mar Biomedica pmid:23235785
de Lalibera IB et al. Meningoencephalitis associated with Mycoplasma pneumoniae. 2012 Jan-Mar Einstein (Sao Paulo) pmid:23045836
Dhillon GS et al. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. 2012 Jan-Feb Clin Transplant pmid:21352378
Onsun N et al. Impact of Helicobacter pylori infection on severity of psoriasis and response to treatment. 2012 Jan-Feb Eur J Dermatol pmid:22063790
Montero-Tinnirello J et al. [Pulmonary hemorrhage due to leptospirosis]. 2012 Jan-Feb Med Intensiva pmid:21592620
Dai WQ et al. The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study. 2012 Jan-Feb Hepatogastroenterology pmid:22260837
Walkey AJ and Wiener RS Macrolide antibiotics and survival in patients with acute lung injury. 2012 Chest pmid:22116799
Reva I et al. Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East. 2012 Microbiol. Immunol. pmid:22211953
Park SJ et al. Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection. 2012 Allergy Asthma Immunol Res pmid:22211173
Falkinham JO et al. Antibacterial activities of dendritic amphiphiles against nontuberculous mycobacteria. 2012 Tuberculosis (Edinb) pmid:22209468
Cuadrado-Lavín A et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. 2012 J. Antimicrob. Chemother. pmid:22687889
Nseir W et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. 2012 Aliment. Pharmacol. Ther. pmid:22646167
Zaater MF et al. Determination and stability assessment of clarithromycin in human plasma using RP-LC with electrochemical detection. 2012 J Chromatogr Sci pmid:22647394
Choi HS et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22654429
Gisbert JP and Calvet X Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. 2012 Aliment. Pharmacol. Ther. pmid:22129228
Nujić K et al. Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities. 2012 Eur. J. Pharmacol. pmid:22209877
Hiramatsu M et al. Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. 2012 Ann. Thorac. Surg. pmid:22119119
Chan A et al. A case of wrist tenosynovitis caused by Mycobacterium kansasii in a renal transplant recipient. 2012 Transpl Infect Dis pmid:22822725
Koh WJ et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. 2012 Am. J. Respir. Crit. Care Med. pmid:22878282
Maurer FP et al. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). 2012 J. Antimicrob. Chemother. pmid:22833642
Kanazu T et al. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats. 2012 Biopharm Drug Dispos pmid:22447511
Togami K et al. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. 2012 Pharmazie pmid:22764569
Fujioka T et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. 2012 J. Gastroenterol. pmid:22065160
Park HG et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. 2012 Aliment. Pharmacol. Ther. pmid:22066530
Liang J et al. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial. 2012 Helicobacter pmid:23066868
Erol E et al. Antibiotic susceptibility patterns of Crossiella equi and Amycolatopsis species causing nocardioform placentitis in horses. 2012 J. Vet. Diagn. Invest. pmid:23051830
Dalkmann P et al. Accumulation of pharmaceuticals, Enterococcus, and resistance genes in soils irrigated with wastewater for zero to 100 years in central Mexico. 2012 PLoS ONE pmid:23049795
Kurugol Z et al. Severe Hemolytic Anemia Associated with Mild Pneumonia Caused by Mycoplasma pneumonia. 2012 Case Rep Med pmid:23049568
Deng ZH et al. Influence of Helicobacter pylori infection on ghrelin levels in children. 2012 World J. Gastroenterol. pmid:23049220
Malfertheiner P et al. Helicobacter pylori: clinical management. 2012 Curr. Opin. Gastroenterol. pmid:23010682
Saracino IM et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. 2012 J Gastrointestin Liver Dis pmid:23256118
Spyridaki A et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. 2012 Antimicrob. Agents Chemother. pmid:22564837
Cajigas-Pezo D et al. [Swelling of right knee in an immunologically compromised patient]. 2012 Enferm. Infecc. Microbiol. Clin. pmid:22521279
McCallum GB et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. 2012 Cochrane Database Syst Rev pmid:23235681
Boyanova L et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. 2012 J. Med. Microbiol. pmid:21873378
Kotsaki A and Giamarellos-Bourboulis EJ Emerging drugs for the treatment of sepsis. 2012 Expert Opin Emerg Drugs pmid:22780561
Fiorini G et al. Newer agents for Helicobacter pylori eradication. 2012 Clin Exp Gastroenterol pmid:22767998
Whittemore KR and Cohen M Imaging and review of a large pre-auricular pilomatrixoma in a child. 2012 World J Radiol pmid:22761984
Kudo T et al. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. 2012 Helicobacter pmid:22759327
Roccarina D et al. Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. 2012 Dig Liver Dis pmid:22743557
Tursi A et al. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. 2012 J Gastrointestin Liver Dis pmid:22720300
Birteksöz-Tan AS and Zeybek Z Postantibiotic effect of various antibiotics on Legionella pneumophila strains isolated from water systems. 2012 Folia Microbiol. (Praha) pmid:22627604
Chang WJ et al. Successful salvage treatment of steroid-refractory bronchiolar COP with low-dose macrolides. 2012 Pathol. Int. pmid:22243785
Burt HJ et al. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4. 2012 Drug Metab. Dispos. pmid:22621802
Lismond A et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. 2012 Int. J. Antimicrob. Agents pmid:22245497
Bermudez LE et al. Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice. 2012 Antimicrob. Agents Chemother. pmid:22615290
Agarwal E et al. Efficacy of local drug delivery of 0.5% clarithromycin gel as an adjunct to non-surgical periodontal therapy in the treatment of current smokers with chronic periodontitis: a randomized controlled clinical trial. 2012 J. Periodontol. pmid:22248223
Khan A et al. Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori. 2012 World J. Gastroenterol. pmid:22611319
Szałek E et al. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? 2012 Pharmacol Rep pmid:23406766
Takeshima F et al. Successful management of cap polyposis with eradication of Helicobacter pylori relapsing 15 years after remission on steroid therapy. 2012 Intern. Med. pmid:22333383
Lawal TO et al. Combination studies of Eucalyptus torelliana F. Muell. leaf extracts and clarithromycin on Helicobacter pylori. 2012 Phytother Res pmid:22318891
Slater CM and Ford AC Treatment of Helicobacter pylori in Latin America. 2012 Lancet pmid:22305216
Gatta L et al. Treatment of Helicobacter pylori in Latin America. 2012 Lancet pmid:22305217
Dicicco M et al. Efficacy of clarithromycin on biofilm formation of methicillin-resistant Staphylococcus pseudintermedius. 2012 BMC Vet. Res. pmid:23171620
Alfakry H et al. The association of serum neutrophil markers and acute coronary syndrome. 2012 Scand. J. Immunol. pmid:22537345
Shaifali I et al. Antibiotic susceptibility patterns of urinary pathogens in female outpatients. 2012 N Am J Med Sci pmid:22536558
Gisbert JP Rescue Therapy for Helicobacter pylori Infection 2012. 2012 Gastroenterol Res Pract pmid:22536225
Lee RP et al. Mycobacterium chelonae infection after total knee arthroplasty: a case report. 2012 J Orthop Surg (Hong Kong) pmid:22535831
Fakheri H et al. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. 2012 Helicobacter pmid:22221615
Georgopoulos S et al. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. 2012 Helicobacter pmid:22221616
Senhorinho GN et al. Occurrence and antimicrobial susceptibility of Porphyromonas spp. and Fusobacterium spp. in dogs with and without periodontitis. 2012 Anaerobe pmid:22609780
Komatsu S et al. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. 2012 Int. J. Oncol. pmid:22200786
Matsuzaki J et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. 2012 Antimicrob. Agents Chemother. pmid:22203601
Adrjanowicz K et al. Molecular dynamics in supercooled liquid and glassy states of antibiotics: azithromycin, clarithromycin and roxithromycin studied by dielectric spectroscopy. Advantages given by the amorphous state. 2012 Mol. Pharm. pmid:22540343
Kobashi Y et al. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. 2012 J. Infect. Chemother. pmid:22205543
Lin Z and Will Y Evaluation of drugs with specific organ toxicities in organ-specific cell lines. 2012 Toxicol. Sci. pmid:22166485
Onoe H et al. Buruli ulcer accompanied by pain in a Japanese patient. 2012 J. Dermatol. pmid:22168180
Lulitanond A et al. Prevalence of β-lactamase-negative ampicillin-resistant haemophilus influenzae isolated from patients of a teaching hospital in Thailand. 2012 Jpn. J. Infect. Dis. pmid:22446118
Liang Y et al. Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes collected between 2005 and 2008 from Chinese children. 2012 J. Med. Microbiol. pmid:22442290
Gomez-Abreo D et al. [Chronic necrotizing pulmonary aspergillosis following an infection by Mycobacterium malmoense]. 2012 Rev Mal Respir pmid:22440310
Lee JH et al. A nanohybrid system for taste masking of sildenafil. 2012 Int J Nanomedicine pmid:22619517
Molina-Infante J et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. 2012 Helicobacter pmid:22759326
Kongchayanun C et al. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. 2012 Helicobacter pmid:22759328
Song JY et al. Case series of mycobacterium abscessus infections associated with a trigger point injection and epidural block at a rural clinic. 2012 Epidemiol Health pmid:22323979
Nguyen TV et al. Eradication of Helicobacter pylori in children in Vietnam in relation to antibiotic resistance. 2012 Helicobacter pmid:22759333
Hirata Y et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. 2012 Int. J. Antimicrob. Agents pmid:22321702
Nizič T et al. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. 2012 Wien. Klin. Wochenschr. pmid:22760494
Yokota S et al. Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line. 2012 Mediators Inflamm. pmid:22761540
Brown-Elliott BA et al. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. 2012 Clin. Microbiol. Rev. pmid:22763637
Pereyre S et al. Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France. 2012 Emerging Infect. Dis. pmid:22305177
Butler CC et al. Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial. 2012 BMJ pmid:22302780
Correia M et al. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. 2012 PLoS ONE pmid:22529974